Bleeding events of direct oral anti-coagulant for treatment of venous thromboembolism in advanced cancer patients.
Not Applicable
- Conditions
- Venous thromboembolism
- Registration Number
- JPRN-UMIN000020275
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 147
Inclusion Criteria
Not provided
Exclusion Criteria
1)Other anti-coagulant or anti-platelet is administered. 2)Other disease requiring anti-coagulant therapy. 3)History of intracranial bleeding. 4)Active bleeding. 5)Thrombolytic therapy is planned. 6)Renal failure (Cre>=1.5mg/dL) 7)Platelet count <100,000/mm3
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the incidence of bleeding during the 12 weeks of treatment of venous thromboembolism with direct oral anti-coagulant.
- Secondary Outcome Measures
Name Time Method The secondary endpoint is the incidence of adverse events during the 12 weeks of treatment of thromboembolism with direct oral anti-coagulant.